157 related articles for article (PubMed ID: 33999416)
1. Anti-CD47 antibody synergizes with cisplatin against laryngeal cancer by enhancing phagocytic ability of macrophages.
Wang J; Zhang H; Yin X; Bian Y
Clin Exp Immunol; 2021 Sep; 205(3):333-342. PubMed ID: 33999416
[TBL] [Abstract][Full Text] [Related]
2. CD47 blockade enhances therapeutic efficacy of cisplatin against lung carcinoma in a murine model.
Cui Z; Xu D; Zhang F; Sun J; Song L; Ye W; Zeng J; Zhou M; Ruan Z; Zhang L; Ren R
Exp Cell Res; 2021 Aug; 405(2):112677. PubMed ID: 34111474
[TBL] [Abstract][Full Text] [Related]
3. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
[No Abstract] [Full Text] [Related]
4. Porcine signal regulatory protein alpha binds to human CD47 to inhibit phagocytosis: Implications for human hematopoietic stem cell transplantation into severe combined immunodeficient pigs.
Boettcher AN; Cunnick JE; Powell EJ; Egner TK; Charley SE; Loving CL; Tuggle CK
Xenotransplantation; 2019 Mar; 26(2):e12466. PubMed ID: 30311702
[TBL] [Abstract][Full Text] [Related]
5. Anti-CD47 antibody suppresses tumour growth and augments the effect of chemotherapy treatment in hepatocellular carcinoma.
Lo J; Lau EY; So FT; Lu P; Chan VS; Cheung VC; Ching RH; Cheng BY; Ma MK; Ng IO; Lee TK
Liver Int; 2016 May; 36(5):737-45. PubMed ID: 26351778
[TBL] [Abstract][Full Text] [Related]
6. Autophagy inhibition induces the repolarisation of tumour-associated macrophages and enhances chemosensitivity of laryngeal cancer cells to cisplatin in mice.
Guo Y; Feng Y; Cui X; Wang Q; Pan X
Cancer Immunol Immunother; 2019 Dec; 68(12):1909-1920. PubMed ID: 31641796
[TBL] [Abstract][Full Text] [Related]
7. Combined strategies for effective cancer immunotherapy with a novel anti-CD47 monoclonal antibody.
Ni H; Cao L; Wu Z; Wang L; Zhou S; Guo X; Gao Y; Jing H; Wu M; Liu Y; Ding J; Zhang P; Zhou Y; Chen B; Xiong Y; Sun J; Prinz B; Baruah H; Geoghegan J; Yu M; Wu W; Liu J
Cancer Immunol Immunother; 2022 Feb; 71(2):353-363. PubMed ID: 34165607
[TBL] [Abstract][Full Text] [Related]
8. Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma.
Edris B; Weiskopf K; Volkmer AK; Volkmer JP; Willingham SB; Contreras-Trujillo H; Liu J; Majeti R; West RB; Fletcher JA; Beck AH; Weissman IL; van de Rijn M
Proc Natl Acad Sci U S A; 2012 Apr; 109(17):6656-61. PubMed ID: 22451919
[TBL] [Abstract][Full Text] [Related]
9. CD47 Blockade Inhibits Tumor Progression through Promoting Phagocytosis of Tumor Cells by M2 Polarized Macrophages in Endometrial Cancer.
Gu S; Ni T; Wang J; Liu Y; Fan Q; Wang Y; Huang T; Chu Y; Sun X; Wang Y
J Immunol Res; 2018; 2018():6156757. PubMed ID: 30525058
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of anti-CD47 antibody-mediated phagocytosis with macrophages against primary effusion lymphoma.
Goto H; Kojima Y; Matsuda K; Kariya R; Taura M; Kuwahara K; Nagai H; Katano H; Okada S
Eur J Cancer; 2014 Jul; 50(10):1836-1846. PubMed ID: 24726056
[TBL] [Abstract][Full Text] [Related]
11. Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response.
Tseng D; Volkmer JP; Willingham SB; Contreras-Trujillo H; Fathman JW; Fernhoff NB; Seita J; Inlay MA; Weiskopf K; Miyanishi M; Weissman IL
Proc Natl Acad Sci U S A; 2013 Jul; 110(27):11103-8. PubMed ID: 23690610
[TBL] [Abstract][Full Text] [Related]
12. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
[TBL] [Abstract][Full Text] [Related]
13. Selective Blockade of the Ubiquitous Checkpoint Receptor CD47 Is Enabled by Dual-Targeting Bispecific Antibodies.
Dheilly E; Moine V; Broyer L; Salgado-Pires S; Johnson Z; Papaioannou A; Cons L; Calloud S; Majocchi S; Nelson R; Rousseau F; Ferlin W; Kosco-Vilbois M; Fischer N; Masternak K
Mol Ther; 2017 Feb; 25(2):523-533. PubMed ID: 28153099
[TBL] [Abstract][Full Text] [Related]
14. Lung-specific exosomes for co-delivery of CD47 blockade and cisplatin for the treatment of non-small cell lung cancer.
Cui Z; Ruan Z; Zeng J; Sun J; Ye W; Xu W; Guo X; Zhang L; Song L
Thorac Cancer; 2022 Oct; 13(19):2723-2731. PubMed ID: 36054073
[TBL] [Abstract][Full Text] [Related]
15. Restoration of miR-340 controls pancreatic cancer cell
Xi Q; Zhang J; Yang G; Zhang L; Chen Y; Wang C; Zhang Z; Guo X; Zhao J; Xue Z; Li Y; Zhang Q; Da Y; Liu L; Yao Z; Zhang R
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32503944
[TBL] [Abstract][Full Text] [Related]
16. Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer.
Cao X; Li B; Chen J; Dang J; Chen S; Gunes EG; Xu B; Tian L; Muend S; Raoof M; Querfeld C; Yu J; Rosen ST; Wang Y; Feng M
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33753567
[TBL] [Abstract][Full Text] [Related]
17. Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance.
Upton R; Banuelos A; Feng D; Biswas T; Kao K; McKenna K; Willingham S; Ho PY; Rosental B; Tal MC; Raveh T; Volkmer JP; Pegram MD; Weissman IL
Proc Natl Acad Sci U S A; 2021 Jul; 118(29):. PubMed ID: 34257155
[TBL] [Abstract][Full Text] [Related]
18. CD47 promotes ovarian cancer progression by inhibiting macrophage phagocytosis.
Liu R; Wei H; Gao P; Yu H; Wang K; Fu Z; Ju B; Zhao M; Dong S; Li Z; He Y; Huang Y; Yao Z
Oncotarget; 2017 Jun; 8(24):39021-39032. PubMed ID: 28380460
[TBL] [Abstract][Full Text] [Related]
19. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis.
Jaiswal S; Jamieson CH; Pang WW; Park CY; Chao MP; Majeti R; Traver D; van Rooijen N; Weissman IL
Cell; 2009 Jul; 138(2):271-85. PubMed ID: 19632178
[TBL] [Abstract][Full Text] [Related]
20. CD47 limits antibody dependent phagocytosis against non-malignant B cells.
Gallagher S; Turman S; Lekstrom K; Wilson S; Herbst R; Wang Y
Mol Immunol; 2017 May; 85():57-65. PubMed ID: 28208074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
